MAEL and gastric cancer: The results revealed that higher MAEL mRNA expression was significantly associated with a shorter overall survival (OS) (hazard ratio [HR] = 1.54, 95% confidence interval [CI]: 1.23–1.92, logrank p-value [p] = 1.2E–4) and first progression survival (FP) (HR = 1.51, CI: 1.18–1.93, p = 8.7E-4) in gastric cancer patients (Figure 1B and 1C).